Updates to the guidelines for the diagnosis and management of multiple myeloma.

Bastuji-Garin, S., Fouchard, N., Bertocchi, M., Roujeau, J.C., Revuz, J. & Wolkenstein, P. (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. The Journal of Investigative Dermatology, 115, 149–153. Ca~ namares Orbis, I., Garc!ıa Mu~ noz, C., Cortijo Cascajares, S. & M!endez Esteban, M.E. (2012) Desensitization to lenalidomide. Farmacia Hospitalaria, 36, 542–543. Spanish. McCarthy, P.L., Owzar, K., Hofmeister, C.C., Hurd, D.D., Hassoun, H., Richardson, P.G., Giralt, S., Stadtmauer, E.A., Weisdorf, D.J., Vij, R., Moreb, J.S., Callander, N.S., Van Besien, K., Gentile, T., Isola, L., Maziarz, R.T., Gabriel, D.A., Bashey, A., Landau, H., Martin, T., Qazilbash, M.H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M.C., Horowitz, M.M., Shea, T.C., Devine, S.M., Anderson, K.C. & Linker, C. (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 366, 1770–1781. Nardone, B., Wu, S., Garden, B.C., West, D.P., Reich, L.M. & Lacouture, M.E. (2013) Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clinical Lymphoma Myeloma & Leukemia, 13, 424–429. Penna, G., Allegra, A., Romeo, G., Alonci, A., Cannav" o, A., Russo, S., D’Angelo, A., Petrungaro, A. & Musolino, C. (2012) Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602. Acta Oncologica, 51, 944–947. Phillips, J., Kujawa, J., Davis-Lorton, M. & Hindenburg, A. (2007) Successful desensitization in a patient with lenalidomide hypersensitivity. American Journal of Hematology, 82, 1030. Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., Abonour, R., Siegel, D.S., Katz, M. & Greipp, P.R., Eastern Cooperative Oncology Group. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet Oncology, 11, 29–37. Richardson, P., Jagannath, S., Hussein, M., Berenson, J., Singhal, S., Irwin, D., Williams, S.F., Bensinger, W., Badros, A.Z., Vescio, R., Kenvin, L., Yu, Z., Olesnyckyj, M., Zeldis, J., Knight, R. & Anderson, K.C. (2009) Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood, 114, 772–778. Seki, J.T., Banglawala, S., Lentz, E.M. & Reece, D.E. (2013) Desensitization to lenalidomide in a patient with relapsed multiple myeloma. Clinical Lymphoma Myeloma & Leukemia, 13, 162–165. Sviggum, H.P., Davis, M.D., Rajkumar, S.V. & Dispenzieri, A. (2006) Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Archives of Dermatology, 142, 1298–1302.